ATHA
Price
$0.29
Change
-$0.01 (-3.33%)
Updated
Jun 27 closing price
Capitalization
11.52M
49 days until earnings call
PBM
Price
$5.37
Change
+$0.46 (+9.37%)
Updated
Jun 30, 01:29 PM (EDT)
Capitalization
2.86M
Interact to see
Advertisement

ATHA vs PBM

Header iconATHA vs PBM Comparison
Open Charts ATHA vs PBMBanner chart's image
Athira Pharma
Price$0.29
Change-$0.01 (-3.33%)
Volume$203.73K
Capitalization11.52M
Psyence Biomedical
Price$5.37
Change+$0.46 (+9.37%)
Volume$300
Capitalization2.86M
ATHA vs PBM Comparison Chart in %
Loading...
ATHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATHA vs. PBM commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATHA is a Buy and PBM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ATHA: $0.29 vs. PBM: $4.91)
Brand notoriety: ATHA and PBM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATHA: 30% vs. PBM: 7%
Market capitalization -- ATHA: $11.52M vs. PBM: $2.86M
ATHA [@Biotechnology] is valued at $11.52M. PBM’s [@Biotechnology] market capitalization is $2.86M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATHA’s FA Score shows that 1 FA rating(s) are green whilePBM’s FA Score has 1 green FA rating(s).

  • ATHA’s FA Score: 1 green, 4 red.
  • PBM’s FA Score: 1 green, 4 red.
According to our system of comparison, PBM is a better buy in the long-term than ATHA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATHA’s TA Score shows that 5 TA indicator(s) are bullish while PBM’s TA Score has 2 bullish TA indicator(s).

  • ATHA’s TA Score: 5 bullish, 5 bearish.
  • PBM’s TA Score: 2 bullish, 2 bearish.
According to our system of comparison, both ATHA and PBM are a good buy in the short-term.

Price Growth

ATHA (@Biotechnology) experienced а -2.64% price change this week, while PBM (@Biotechnology) price change was +3.15% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.65%. For the same industry, the average monthly price growth was +32.92%, and the average quarterly price growth was +6.78%.

Reported Earning Dates

ATHA is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+3.65% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATHA($11.5M) has a higher market cap than PBM($2.86M). ATHA YTD gains are higher at: -49.719 vs. PBM (-70.803). ATHA has more cash in the bank: 36.7M vs. PBM (1.93M). ATHA has less debt than PBM: ATHA (1.12M) vs PBM (2.5M).
ATHAPBMATHA / PBM
Capitalization11.5M2.86M402%
EBITDA-77.65MN/A-
Gain YTD-49.719-70.80370%
P/E RatioN/A0.12-
Revenue0N/A-
Total Cash36.7M1.93M1,899%
Total Debt1.12M2.5M45%
TECHNICAL ANALYSIS
Technical Analysis
ATHAPBM
RSI
ODDS (%)
Bearish Trend 4 days ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
69%
Momentum
ODDS (%)
Bearish Trend 4 days ago
87%
Bullish Trend 4 days ago
85%
MACD
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 14 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 11 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 4 days ago
73%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ATHA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PBM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CXDO6.020.06
+1.01%
Crexendo
AEE95.31-0.07
-0.07%
Ameren Corp
CLVT4.31-0.09
-2.05%
Clarivate Plc
BNZI0.57-0.02
-2.96%
Banzai International Inc
ANAB22.47-0.91
-3.89%
AnaptysBio

ATHA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATHA has been loosely correlated with OGEN. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ATHA jumps, then OGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATHA
1D Price
Change %
ATHA100%
-2.64%
OGEN - ATHA
38%
Loosely correlated
+16.05%
MNKD - ATHA
33%
Poorly correlated
-0.27%
SNGX - ATHA
32%
Poorly correlated
-0.73%
ZYME - ATHA
31%
Poorly correlated
+0.81%
PCVX - ATHA
31%
Poorly correlated
-0.91%
More

PBM and

Correlation & Price change

A.I.dvisor tells us that PBM and ATHA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PBM and ATHA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PBM
1D Price
Change %
PBM100%
-3.89%
ATHA - PBM
30%
Poorly correlated
-2.64%
SLRX - PBM
29%
Poorly correlated
-0.01%
MNMD - PBM
27%
Poorly correlated
-2.82%
CRBU - PBM
26%
Poorly correlated
-6.67%
PRME - PBM
25%
Poorly correlated
-8.68%
More